Yahoo · Sep 22, 2026
Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark
VR
NASDAQ · VRDN
Viridian Therapeutics, Inc.
Healthcare · Biotechnology
$19.00
Down-$0.78 (-4.11%)
Updated Oct 7, 2026, 12:13 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.64B
- P/E ratio
- -7.73
- Dividend yield
- 0.00%
- 52-week range
- $13.18 – $30.42
- Volume
- 2.65M
- Avg. volume
- 1.41M
Price performance · VRDN
VRDN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
VRDN closed at $19.00 after 20 trading sessions, down 18.00% for the selected period.
- Last close
- $19.00
- Period change
- -18.00%
- Period low
- $18.99
- Period high
- $23.17
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $19.41 | $19.59 | $18.83 | $19.00 | 2.65M |
| Oct 2, 2026 | $19.16 | $19.545 | $18.92 | $19.40 | 1.52M |
| Oct 1, 2026 | $20.61 | $20.61 | $18.99 | $18.99 | 3.38M |
| Sep 30, 2026 | $20.27 | $20.745 | $20.00 | $20.59 | 1.4M |
| Sep 29, 2026 | $20.685 | $20.85 | $19.73 | $19.995 | 1.23M |
| Sep 28, 2026 | $20.31 | $20.705 | $20.03 | $20.57 | 1.34M |
| Sep 25, 2026 | $20.75 | $21.005 | $20.155 | $20.47 | 2.09M |
| Sep 24, 2026 | $21.10 | $21.25 | $20.22 | $20.66 | 2.21M |
| Sep 23, 2026 | $22.11 | $22.185 | $21.20 | $21.43 | 2.86M |
| Sep 22, 2026 | $22.02 | $22.33 | $21.54 | $22.12 | 1.46M |
| Sep 21, 2026 | $22.28 | $22.40 | $21.53 | $21.58 | 1.75M |
| Sep 18, 2026 | $21.99 | $22.17 | $21.80 | $22.00 | 5.38M |
| Sep 17, 2026 | $22.88 | $22.97 | $21.72 | $21.93 | 1.27M |
| Sep 16, 2026 | $21.89 | $22.46 | $21.68 | $22.44 | 1.67M |
| Sep 15, 2026 | $21.98 | $22.14 | $21.40 | $21.83 | 1.21M |
| Sep 14, 2026 | $21.47 | $22.30 | $21.2704 | $22.20 | 1.3M |
| Sep 11, 2026 | $22.48 | $22.695 | $21.185 | $21.24 | 944.08K |
| Sep 10, 2026 | $22.40 | $22.60 | $21.99 | $22.29 | 1.31M |
| Sep 9, 2026 | $23.11 | $23.58 | $22.70 | $22.73 | 1.58M |
| Sep 8, 2026 | $22.38 | $23.835 | $22.2201 | $23.17 | 1.83M |
Latest VRDN news
The latest Smart Investors Daily articles mentioning VRDN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VRDN research
Overview
Company profile and research snapshot.
Company profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.57
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Jun 30, 2026 | Wedbush | Outperform | — |
| Jun 30, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 22, 2026
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
SeekingAlpha · Sep 17, 2026
Viridian Therapeutics: Two Products, One Commercial Buildout
Viridian Therapeutics aims to leverage its infrastructure for both Lumvoa and elegrobart, potentially improving franchise economics. Read more on VRDN.
Yahoo · Sep 2, 2026
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
